A Phase 4 interventional study of Follitropin Alfa in Female Infertility, sponsored by MinaPharm Pharmaceuticals. Status unknown at 2 sites in Egypt. Open to female participants aged 18 Years to 38 Years. Per ClinicalTrials.gov, last updated 2017-08-30.
Sponsored by MinaPharm Pharmaceuticals · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Infertility, Female with a site in Egypt — 6 open to participants now, 6 under way, none of them phase 3. Infertility, Female · Egypt.
Among the 60 studies in Infertility, Female with a site in Egypt, this one is the 7th largest by planned enrollment of the 46 interventional ones that give a count, is one of 9 that started in 2017, is one of 15 in phase 4, and was the 6th registered.
552 studies on the registry are indexed under Infertility, Female; 135 are open to participants now.
Browse Infertility, Female studies →6 of the 60 studies in Infertility, Female with a site in Egypt are open now. Recruiting first, the newest first:
Beni-Suef University · Sites in Egypt
Ages 18–43 · Women only
Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy · Sites in Egypt
Ages 20–40 · Women only
Assiut University · Sites in Egypt
Ages 18–40 · Women only
Assiut University · Sites in Egypt
Ages 18–35 · Women only
Zagazig University · Sites in Egypt
Ages 21–40 · Women only · Healthy volunteers
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 90 Infertility, Female studies recruiting now, 11 (12%) set no upper age limit and 79 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 38 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 6 · Phase 4 15
First in 2013; this study’s year is marked. 9 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 100 across 378 interventional studies indexed under Infertility, Female.
Median enrollment 141 across the 46 interventional studies, 163 across the 14 observational. Of the 32 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 60 have an industry lead sponsor. The 10 most frequent:
MinaPharm Pharmaceuticals is the lead sponsor of 7 studies on the registry; none are open to participants now.
MinaPharm Pharmaceuticals has 1 study filed under Infertility, Female — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 60 studies in Infertility, Female with a site in Egypt, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to record Efficacy, Safety and tolerability of Gonapure® prescribed for female subjects with infertility Undergoing IVF/ICSI
Gonapure® is a human follicle stimulating hormone (FSH) preparation of recombinant DNA origin and contains no luteinizing hormone (LH) activity.
FSH stimulates ovarian follicular growth in women who do not have primary ovarian failure. FSH, the active component of Gonapure® is the primary hormone responsible for follicular recruitment and development. In order to affect final maturation of the follicle and ovulation in the absence of an endogenous LH surge, human chorionic gonadotropin (hCG) must be given following the administration of FSH, when monitoring of the patient indicates that sufficient follicular development has occurred. There is inter-patient variability in response to FSH administration.
The dosage and schedule of treatment for female infertility must be determined according to the needs of each patient; it is usual to monitor response by studying the patient's serum oestrogen level and/or by ultrasonic visualization of follicles.
Treatment should be started within the first 7 days of the menstrual cycle. Treatment is usually begun with 75 to 450 International units daily by intramuscular injection for 7 to 10 days; followed by individual adjustments according to the patient's follicular response i.e. until an adequate, but not excessive, response is achieved.
The investigator will decide the starting dose according to the standard clinical practice (and within the approved label).
Treatment is then stopped and followed after 1 or 2 days by a single dose of human chorionic Gonadotropin 10000 International units to induce oocyte maturation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Follitropin Alfa (Gonapure)
Drug: Follitropin Alfa
Patients must be prescribed Follitropin Alfa (Gonapure®)
Also known as: Gonapure ®
Number of oocytes retrieved on the day of Ovum Pick-Up
Time frame: 50 days after baseline visit (EOS)
Number of Mature Oocytes (MII) Retrieved Per Participant
Metaphase II (MII): The oocyte is in the second phase of meiosis and is mature. Oocytes at this stage of maturity are ready for fertilization. Mean number of Mature oocytes (MII) retrieved on the day of ovum pick up (OPU) will be calculated. Oocyte retrieval is a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.
Time frame: 50 days after baseline visit (EOS)
Quality of Oocytes Retrieved per participant
It is graded on a good-fair-poor scale: * Good * Clear cytoplasm/normal shape * Single distinct polar body * Clear/thin zona pellucida * Fair * Slightly grainy cytoplasm/misshapen * Fragmented/abnormal polar body * Slightly pigmented/amorphous zona * Cytoplasmic bodies * PV (vitelline platelets) debris * Poor * Dark/grainy cytoplasm/misshapen * \>1 polar body structure * Pigmented/thickened zona * Vacuoles * PV (vitelline platelets) debris * Good Quality embryos per participant. Those embryos that have reached the most advanced developmental stage and have the least cellular fragmentation (Grades "A" and/or "B") will be considered Good Quality embryos and will be selected for transfer. * Number of transferred embryos per participant. * Percentage of Participants with Clinical Pregnancy. Clinical pregnancy is defined by the number of sacs and hearts with activity per ultrasound scan.
Time frame: 50 days after baseline visit (EOS)
Eventual AE/SAEs related to the administration of Gonapure®
Time frame: 50 days after baseline visit (EOS)
Total & Mean Gonapure ® Daily Dose
Time Frame: Start of treatment until end of stimulation cycle
Time frame: 14 days
Number of follicles ≥ 18 mm on day of administration of hCG
Time frame: 50 days after baseline visit (EOS)
Number of Participants with Multiple Pregnancies
Multiple pregnancies were defined as 2 or more fetal hearts with activity.
Time frame: 50 days after baseline visit (EOS)
Number of Participants with Ovarian Hyperstimulation Syndrome
OHSS is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid Accumulation, hemoconcentration, and increased blood clotting.
Time frame: 50 days after baseline visit (EOS)
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2017 (actual). Primary completion is estimated for Dec 2017, 10 months after the start.
Of 37 phase 4 interventional studies under Infertility, Female, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 10 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Follitropin alfa
MinaPharm Pharmaceuticals